Labcorp delivered mixed third-quarter results, with higher sales and raised profit | Labcorp reported solid third-quarter ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

With a new approach to creating thymus-targeted medicines for autoimmune diseases, Zag Bio has emerged from stealth with the ...

Edesa Biotech has shared data from its truncated phase 3 respiratory failure trial, linking the anti-TLR4 antibody to ...

Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns ...

Jupiter Endovascular, which was formed by Neptune Medical a little more than a year ago, shared positive results from the ...

Chronic conditions “are widespread yet remain invisible” with many people living with long-term disorders “masking” their ...

Eli Lilly and computing giant Nvidia are teaming up to build a new supercomputer that the pair say will be the most powerful owned and operated by a pharmaceutical company.

Swiss CDMO Lonza is making a move to strengthen and speed up quality control testing with the purchase of French rapid ...

Chinese life science contracting giant WuXi AppTec is taking another step to zero in on its core offerings by hiving off two China-based subsidiaries. | By separating itself from its China-based CRO ...

The biotech has a deck of RASP modulators. As Aldeyra has accrued evidence in a range of indications, management has shuffled the pack by changing its priority assets in specific diseases. The company ...

The number of biopharma M&A deals announced so far this year is higher than the yearly average for the last 15 years, while ...